144 related articles for article (PubMed ID: 15711199)
41. [Graft rejection reaction and immunosuppression following heart transplantation].
Leonardi L; Lüthy A; Mondada C; Waser M; Laske A; Turina M; Gallino A
Ther Umsch; 1990 Feb; 47(2):147-51. PubMed ID: 2180104
[TBL] [Abstract][Full Text] [Related]
42. Recurrent or persistent cardiac allograft rejection: therapeutic options and recommendations.
Kirklin JK; Bourge RC; McGiffin DC
Transplant Proc; 1997 Dec; 29(8A):40S-44S. PubMed ID: 9414674
[No Abstract] [Full Text] [Related]
43. Mannose-binding lectin deficiency offers protection from acute graft rejection after heart transplantation.
Fildes JE; Shaw SM; Walker AH; McAlindon M; Williams SG; Keevil BG; Yonan N
J Heart Lung Transplant; 2008 Dec; 27(12):1353-6. PubMed ID: 19059118
[TBL] [Abstract][Full Text] [Related]
44. The pathology of heart allograft rejection.
Winters GL
Arch Pathol Lab Med; 1991 Mar; 115(3):266-72. PubMed ID: 2001167
[TBL] [Abstract][Full Text] [Related]
45. Identification of patients not requiring endomyocardial biopsies late after cardiac transplantation.
Brunner-La Rocca HP; Kiowski W
Transplantation; 1998 Feb; 65(4):533-8. PubMed ID: 9500629
[TBL] [Abstract][Full Text] [Related]
46. Heart allograft rejection under varying immunosuppressive protocols as evaluated by endomyocardial biopsy.
Imakita M; Tazelaar HD; Billingham ME
J Heart Transplant; 1986; 5(4):279-85. PubMed ID: 3305819
[TBL] [Abstract][Full Text] [Related]
47. The utility of 6-month protocol renal biopsy under modern immunosuppression.
Yango A; Gohh R; Wang LJ; Morrissey P; Shih M; Lowery K; Charpentier K; Gautam A; Mendonca C; Kumar S; Dworkin L; Monaco A
Clin Nephrol; 2008 Dec; 70(6):490-5. PubMed ID: 19049705
[TBL] [Abstract][Full Text] [Related]
48. Spectrum of humoral rejection after pediatric heart transplantation.
Zales VR; Crawford S; Backer CL; Lynch P; Benson DW; Mavroudis C
J Heart Lung Transplant; 1993; 12(4):563-71; discussion 572. PubMed ID: 8369319
[TBL] [Abstract][Full Text] [Related]
49. An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients.
Itescu S; Tung TC; Burke EM; Weinberg AD; Mancini D; Michler RE; Suciu-Foca NM; Rose EA
Lancet; 1998 Jul; 352(9124):263-70. PubMed ID: 9690405
[TBL] [Abstract][Full Text] [Related]
50. Should we be doing routine biopsy after heart transplantation in a new era of anti-rejection?
Patel JK; Kobashigawa JA
Curr Opin Cardiol; 2006 Mar; 21(2):127-31. PubMed ID: 16470149
[TBL] [Abstract][Full Text] [Related]
51. The value of needle renal allograft biopsy. I. A retrospective study of biopsies performed during putative rejection episodes.
Matas AJ; Sibley R; Mauer M; Sutherland DE; Simmons RL; Najarian JS
Ann Surg; 1983 Feb; 197(2):226-37. PubMed ID: 6297416
[TBL] [Abstract][Full Text] [Related]
52. Immune function surveillance: association with rejection, infection and cardiac allograft vasculopathy.
Heikal NM; Bader FM; Martins TB; Pavlov IY; Wilson AR; Barakat M; Stehlik J; Kfoury AG; Gilbert EM; Delgado JC; Hill HR
Transplant Proc; 2013; 45(1):376-82. PubMed ID: 23267802
[TBL] [Abstract][Full Text] [Related]
53. Echocardiographic characteristics of biopsy-proven cellular rejection in infant heart transplant recipients.
Santos-Ocampo SD; Sekarski TJ; Saffitz JE; Bridges ND; Huddleston CB; Spray TL; Canter CE
J Heart Lung Transplant; 1996 Jan; 15(1 Pt 1):25-34. PubMed ID: 8820080
[TBL] [Abstract][Full Text] [Related]
54. Reversibility of cardiac xenograft rejection in primates.
McManus RP; Kinney T; Komorowski R; Hunter J
J Heart Lung Transplant; 1991; 10(4):567-76. PubMed ID: 1911800
[TBL] [Abstract][Full Text] [Related]
55. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
[TBL] [Abstract][Full Text] [Related]
56. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
57. Natural course of moderate cardiac allograft rejection (International Society for Heart Transplantation grade 2) early and late after transplantation.
Brunner-La Rocca HP; Sütsch G; Schneider J; Follath F; Kiowski W
Circulation; 1996 Sep; 94(6):1334-8. PubMed ID: 8822989
[TBL] [Abstract][Full Text] [Related]
58. Effect of early cyclosporine levels on kidney allograft rejection.
Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
[TBL] [Abstract][Full Text] [Related]
59. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients.
Sayegh MH; Zheng XG; Magee C; Hancock WW; Turka LA
Transplantation; 1997 Dec; 64(12):1646-50. PubMed ID: 9422396
[TBL] [Abstract][Full Text] [Related]
60. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease.
Michaels PJ; Espejo ML; Kobashigawa J; Alejos JC; Burch C; Takemoto S; Reed EF; Fishbein MC
J Heart Lung Transplant; 2003 Jan; 22(1):58-69. PubMed ID: 12531414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
